Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
Benzinga Newsdesk 2 days ago
News
Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune
- Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia
- Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition
- Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval